Vilanterol

CHEMBL1198857 Phase 4 अनुमोदित Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
486.4 g/mol
LogP
3.8
Phase
4

Vilanterol is a long-acting beta-2 adrenergic agonist (LABA) with ultra-long duration of action (>24 hours) that activates beta-2 receptors in bronchial smooth muscle, producing sustained bronchodilation through cAMP-mediated relaxation. It is used exclusively in combination with inhaled corticosteroids (fluticasone furoate) or as a dual bronchodilator (with umeclidinium) for maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Its 24-hour duration enables once-daily dosing.

आणविक भार

486.4000 g/mol

LogP

3.80

TPSA

91.20 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D संरचना

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O

InChI

InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1

Molecular Formula

C24H33Cl2NO5

HBD / HBA

4 / 6

घूर्णनीय बंधन

16

भारी परमाणु

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

Vilanterol is a long-acting beta-2 adrenergic agonist (LABA) with ultra-long duration of action (>24 hours) that activates beta-2 receptors in bronchial smooth muscle, producing sustained bronchodilation through cAMP-mediated relaxation. It is used exclusively in combination with inhaled corticosteroids (fluticasone furoate) or as a dual bronchodilator (with umeclidinium) for maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Its 24-hour duration enables once-daily dosing.

Yes, Vilanterol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1198857. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 10184665. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.